Kornimate/medical-research-clean huggingface dataset:
lifepearl anthracyclin registry in selective chemo-embolization of patients with unresectable hcc (paris registry)

Conditions: Hepatocellular Carcinoma

Summary: the main purpose of this registry is to assess liver toxicity, treatment efficacy, and safety of deb-tace using anthracyclin loaded lifepearls for treatment of patients with unresectable hepatocellular carcinoma allocated to tace treatment.

hepatocellular carcinoma (hcc) is the fifth most common type of cancer in men and the eight in women and is the third most common cause of death from cancer worldwide. the overall incidence of hcc remains high in developing countries and is steadily rising in most industrialized countries. available treatment options depend on the size, number, and location of tumors; degree of cirrhosis, if present; and comorbidities; overall performance status; patency of portal vein; and presence of metastatic disease. they include surgical (liver resection, liver transplantation), medical (e.g. sorafenib...), ablative (ethanol ablation, radiofrequency ablation, cryoablation) and intra-arterial (chemoembolization, radioembolization) modalities. trans arterial chemo-embolization (tace) with various drugs (anthracyclines being among the most commonly used ones) has been an important therapeutic option for treatment of patients with intermediate stage hcc according to bclc/eortc guidelines (ref). in order to maximize therapeutic efficacy of tace, chemotherapy loadable beads were developed allowing to lower systemic toxicity of chemotherapy, to deliver high and sustained chemotherapy concentration to the tumor, and to prolong delivery of drug and embolization to the tumor. the purpose of this registry is to evaluate liver and systemic toxicity, treatment efficacy, and safety of drug elutable beads -tace using anthracyclin loaded life-pearls -tace for unresectable hepatocellular carcinoma.

Eligibility criteria:
inclusion criteria: * patients, more than 18 years old, with unresectable hepatocellular carcinoma eligible for treatment with anthracyclin loaded lifepearls, allocated to tace treatment at multidisciplinary tumor board and who agree to data collection in the registry by signing informed consent form. exclusion criteria: * this is an observational registry and there are no exclusion criteria apart from patient refusal.

Keywords: hcc lifepearl
effects of ai assisted follow-up strategy on secondary prevention in cabg patients

Conditions: Coronary Heart Disease; Artificial Intelligence; Sleep Apnea

Summary: the present study is trying to find out whether artificial intelligence assisted follow-up strategy will improve secondary prevention in cabg patients. in addition, we will test whether rural patients may have more benefits under the new follow-up strategy based on the artificial intelligence device compared with urban patients.

there are a large population of coronary heart disease patients in china, which needs more attention to optimize the secondary prevention and improve the prognosis. secondary prevention has been showing the effects of improving symptoms, preventing disease progression, improving prognosis, and reducing mortality in patients received coronary artery bypass grafting (cabg) surgery. in this study, we are trying to evaluate the effectiveness of artificial intelligence (ai) assisted follow-up strategy on secondary prevention for patients received cabg surgery. and we are trying to find out whether there is difference in secondary prevention of coronary heart disease between urban and rural patients.

Eligibility criteria:
inclusion criteria: 1. age between 18-70, male or female 2. received isolated cabg procedure due to coronary artery disease 3. having a smartphone and are willing to cooperate 4. signing written informed consent exclusion criteria: 1. patients undergoing cabg + valve replacement surgery 2. postoperative hospital stays more than 10 days (due to limited postoperative follow-up time and unstable condition such as incision infection, angina, etc.) 3. patients with lung, liver, and kidney failure (due to organ dysfunction which needs more professional health care and not suitable for this trial) 4. patients with urinary system diseases (getting up during sleep, which will interfere with sleep monitoring) 5. patients mentally or legally disabled 6. breastfeeding or pregnant women 7. end-stage disease, estimated survival time is less than 3 months 8. participate in other perioperative intervention studies at the same time

Keywords: artificial intelligence
core stability and parkinson disease

Conditions: Parkinson Disease

Summary: patients with parkinson's disease frequently present impaired postural control that leads to loss of stability and increased risk of falls.core system, includes passive structures of the thoracolumbar spine and pelvis that work as a unit to stabilize the body and spine against forces generated from distal body segments as well as forces generated from expected or unexpected perturbations.the objective of this study was to evaluate the effects of an intervention based on core stability in patients with parkinson's disease.

core muscle coordination is important because lack of sufficient core muscle coordination can lead to decreased efficiency of postural control and functional activity. clinical manifestations of patients with parkinson's disease include postural instability. core system could be relevant to be included in an intervention. thus, the objective of this study was to evaluate the effects of an intervention based on core stability in patients with parkinson's disease.

Eligibility criteria:
inclusion criteria: * parkinson's disease diagnosis. * stable medication usage * able to maintain standing independent exclusion criteria: * cognitive impairment * comprehension deficits that prevented them from following verbal commands
preventive potential of bilirubin

Conditions: Mild Hyperbilirubinaemia

Summary: the prevalence of mild hyperbilirubinemia, also known as gilbert´s syndrome, is usually defined using an unconjugated bilirubin (ucb) blood concentration above 17.1 µmol/l. the prevalence of gs is remarkably common, affecting 5-10% (depending on ethnicity and gender) of the adult population. the aim of this project is to investigate whether there is a difference in health related marker between 60 subjects with gilbert´s syndrome (mild hyperbilirubinaemia) and 60 age and gender matched control subjects.


Eligibility criteria:
inclusion criteria: in general * signed declaration of consent * age: 20-80 years * liver enzymes (ast, alt, ggt) \< 1.5x over norm values * non smoking * moderate physical activity * ability to communicate with the study team in the local language to understand the study procedure cases (gs): * total blood bilirubin \> 1.2 mg/dl * unconjugated bilirubin \> 1 mg/dl controls (non-gs): * total blood bilirubin ≤ 1.2 mg/dl * unconjugated bilirubin ≤ 1 mg/dl exclusion criteria: in general * age \ 80 years * cardiovascular diseases * liver diseases (including hep b and c) * cholelithiasis * hemolysis * renal diseases * active tumors * diabetes mellitus * smoking * professional athletes * subjects with organ transplants * intake of antioxidants within the last 4 weeks * intake of liver influencing medication within the last 5 weeks cases (gs): * total blood bilirubin ≤ 1.2 mg/dl * unconjugated bilirubin ≤ 1 mg/dl controls (non-gs): * total blood bilirubin \> 1.2 mg/dl * unconjugated bilirubin \> 1 mg/dl
evaluate the efficacy of magnesium isoglycyrrhizinate in the prevention of chemotherapy related acute liver injury

Conditions: Neoplasms; Liver Injury

Summary: this purpose of this study is to evaluate the evaluate the efficacy of magnesium isoglycyrrhizinate injection in the prevention of antineoplastic chemotherapy related acute liver injury.

total subjects: 2040, experimental group of 1360 patients, control group of 680 patients. according to the study subjects receiving antineoplastic chemotherapy, subjects are stratified randomize.

Eligibility criteria:
inclusion criteria: 1. male or female aged 18-75 years; 2. patients with malignant tumor accord with chemotherapy indication, candidate to a chemotherapy treatment, disease is not restricted; 3. accorded with the following chemotherapy plan: included cis-platinum, ≥60mg/m2/course; included oxaliplatin, ≥85mg/m2/course; included cyclophosphamide, ≥600mg/m2/course; included gemcitabine, ≥60mg/m2/course; 4. ecog≤2; 5. estimates survival time≥3 months; 6. tbil≤1.0×uln, alt、ast≤1.0×uln; blood examination, uronoscopy, stool examination, renal function tests and electrocardiogram are normal; 7. patients have been apart from the previous chemotherapy to finish above 2 weeks (including 2 weeks). exclusion criteria: 1. patients with partial liver radiotherapy; 2. hepatitis b or c virus replication in the state, the patient will need antiviral therapy; 3. patients have serious heart diseases, liver kidney diseases, or metabolism function disorder; 4. patients combined with cellular immune therapy; 5. within 2 weeks of application or currently possible applications of drugs(polyene phosphatidylcholine, reduced glutathione, tiopronin and other hepatoprotective and choleretic drugs), interference with the study; 6. pregnancy, or patients during breast feeding; 7. patients have known hypersensitivity to glycyrrhizin; 8. patients are participating, or have participated in other clinical studies of new drugs within 4 weeks.
monitoring outpatient blood volume in heart failure

Conditions: Heart Failure

Summary: in patients discharged following heart failure treatment, the consistency of blood volume status and components over time is unknown. the primary objective is to describe the rate of change, if any, of the plasma volume and red blood cell volume following hospitalization and discharge of patients with heart failure.

over 6 million americans suffer from heart failure, one of the most prevalent and deadly diseases. high 30-day readmission and mortality rates have persisted despite advances in care. clinical guidelines suggest blood volume assessment and clinical management to euvolemia or normal blood volume, but standard methods of blood volume diagnosis have been shown to be unreliable. fda-cleared blood volume analysis (bva) has been used to quantify otherwise undiagnosed blood volume derangements in heart failure and other indications. also, care guided by bva has been demonstrated to improve inpatient heart failure readmission and mortality. a similar analysis has not previously been performed immediately following hospital discharge, though this period is understood to be challenging due to high variability of patient status, physiology, and compliance. this is a prospective, single-center, observational open-label study. the primary objective is to quantify changes to plasma volume and red blood cell volume over a 12 week period post-discharge.

Eligibility criteria:
inclusion criteria: * hospitalized male and female patients with primary or secondary admission diagnosis of acute heart failure exacerbation * \> 18 years of age * able and willing to provide consent * reduced or preserved lvef exclusion criteria: * diagnosed with current acute strokes * pregnant women * severe hypotension requiring resuscitation, intubation or circulatory support * cardiogenic shock * patients with known cardiac amyloid and hypotension * known allergy to iodine or iodinated albumin

Keywords: plasma volume red blood cell volume blood volume diuresis
comparisons of two low-density lipoprotein apheresis systems in patients with homozygous familial hypercholesterolemia

Conditions: Homozygous Familial Hypercholesterolemia

Summary: homozygous familial hypercholesterolemia (hofh) is characterized by a six- to eight-fold raise in plasma ldl-cholesterol (ldl-c) concentrations and atherosclerotic coronary artery disease usually occur before the age of 20 if untreated. lipid apheresis (la) has been proved to be a reliable method to decrease ldl-c concentrations and therefore decrease cardiovascular disease risk in hofh. the objective of this crossover study was to compare efficacy of la performed with heparin-induced extracorporeal ldl precipitation to dextran sulfate adsorption on the reduction of lipids, inflammatory markers, adhesion molecules and ldl particles size in a cohort of hofh subjects.


Eligibility criteria:
inclusion criteria: * aged between 18-65 years * subjects with homozygous familial hypercholesterolemia: * carrier of a mutation in the ldl receptor gene exclusion criteria: * subjects with a previous history of cardiovascular disease * subjects with type 2 diabetes * were pregnant or nursing; * subjects with a history of cancer * subjects with acute liver disease, hepatic dysfunction, or persistent elevations of serum transaminases * subjects with a secondary hyperlipidemia due to any cause * history of alcohol or drug abuse within the past 2 years * hormonal treatment * subjects who are in a situation or have any condition that, in the opinion of the investigator, may interfere with optimal participation in the study
effect of extra virgin olive oil on postprandial blood glucose in type 2 diabetes mellitus patients

Conditions: Diabetes Mellitus, Type 2

Summary: extra virgin olive oil (evoo) is known for its cardiovascular effects and its effect on glucose lowering. however, the effects of evoo on the blood glucose of type 2 diabetes mellitus filipino patients has not been studied. the investigators aimed to determine whether a significant difference exists in meals containing evoo versus meals without evoo among type 2 diabetes mellitus patients. thirteen patients were included in this randomized controlled cross-over trial. they were randomized to receive a meal with or without evoo followed by a one week wash out period, where they were given the other intervention. the primary outcome is the trans-meal blood glucose, which is calculated as the percent change in 2-hour postprandial blood glucose.

during their first visit, the participants were oriented on the conduct of the study. they were advised to be compliant with their medications throughout the duration of the trial. on their second visit, participants were asked to do a six to eight-hour overnight fast, and their fasting blood sugar was drawn. serum samples were analyzed through the hexokinase method. the participants were then randomly allocated (first allocation) by the dietician through a coin toss to receive a standard breakfast without evoo or a meal admixed with one tablespoon of evoo. the standard meals were labeled with serial numbers, and both the participants and the investigator were blinded to the intervention. the meals were consumed steadily in 15 to 20 minutes, after which, the food containers were collected to ensure its full consumption. breakfast was chosen in order to avoid a second meal bias. the participants were asked to sit in the waiting area of the laboratory until the 2-hour postprandial blood sugar was due to be drawn. after a one-week washout period, the participants were asked to come back for a cross over to the other treatment arm (second allocation). the participants were given the same test meal to ensure that that the glycemic index of the food remained constant.

Eligibility criteria:
inclusion criteria: 1. patients aged 30-65 years old 2. diagnosed with type 2 diabetes mellitus 3. body mass index under the overweight or obese class i category (by asia pacific guidelines) exclusion criteria: 1. pregnant patients 2. patients with history of frequent hypoglycemic episodes 3. those at high risk of developing ketoacidosis and hyperglycemic hyperosmolar syndrome 4. those with identified acute stress during the study (illness, fever, trauma leading to hospitalization) 5. current intake of steroids 6. olive oil allergy or intolerance 7. digestive disorders

Keywords: diabetes mellitus type 2 diet therapy extra virgin olive oil
a study to compare the efficacy and safety of tacrolimus capsules with leflunomide tablets in lupus nephritis patients

Conditions: Lupus Nephritis

Summary: the purpose of this study is to compare the efficacy and safety of tacrolimus capsules with leflunomide tablets in the treatment of lupus nephritis.


Eligibility criteria:
inclusion criteria: * body weight 40-100kg * diagnosed as systemic lupus erythematosus, (according to american college of rheumatology diagnostic criteria,1997) * diagnosed as type iii/ iv of lupus nephritis by renal biopsy within 6 months * 24hr proteinuria ≥2g and/or active urinary sediments exclusion criteria: * receiving immunosuppressant * receiving routine treatment of tacrolimus and leflunomide within 1 month * receiving nonsteroidal anti-inflammatory drugs (nsaids) within 1 months before the study * history of allergy to tacrolimus and leflunomide * anticipated maintenance dialysis persisted over 8 weeks; or already being dialyzed over 2 weeks before recruitment * planning to receive kidney transplantation or in the near future or having a history of undergoing kidney transplantation * serum creatinine (scr) ≥3mg/dl or estimated glomerular filtration rate (egfr) \< 30ml/min * diabetes mellitus patients

Keywords: prograf nephritis leflunomide immunosuppressant
urinary markers by spectroscopy: diagnostic aid in oncology - application to urological cancers

Conditions: Urinary Bladder Tumour

Summary: this study aims to evaluate the performance of vibrational spectroscopy (infrared and raman spectroscopy techniques) in bladder cancer diagnosis using urine samples.

urologic cancers affect the organs and structures of the male and female urinary tract and the male reproductive system. bladder cancer (bca) is the second urological cancer in incidence after prostate cancer and represents the 10th most common cancer in the world. this cancer has high recurrence and progression rates. cystoscopy and urine cytology are the current gold-standard examination for bladder cancer. nevertheless, the first is invasive and the latter has low sensitivity especially for low-grade bladder cancer. therefore, it is critical to implement accurate, non- invasive and sensitive examination tool to diagnose patients with bladder cancer at an early stage. on the one hand, urine is collected non-invasively and considered as a proximal biofluid from bladder. on the other hand, vibrational spectroscopy including infrared and raman spectroscopy is widely used for the analysis of biological samples and provides a molecular fingerprint of the sample with minimum or no sample preparation. applied on urine, this technique may offer interesting alternative for bladder cancer diagnosis and monitoring. hence, this research project aims to evaluate the analytical capabilities of urinary vibrational spectroscopy with the objective of developing a diagnostic test for urothelial bladder cancer. the study is planned for 36 months. patients that approve their participation in the study will respond to a questionnaire allowing us to have clinical information. from these patients, urine samples will be collected in urology department of reims university hospital. urine samples will be directly analyzed by fourier transform infrared spectroscopy and/or surface-enhanced raman spectroscopy then stored at -80°c for further analysis.

Eligibility criteria:
inclusion criteria: * must be over 18 years of age * able to give consent and understand the purpose the study * agree to participate in the study and having signed the non-objection document * admitted to a urology consultation for cystoscopy exclusion criteria: patients with any of the following criteria will not be included in the study * refused to participate in the study or unable to give consent * without a native bladder * with a bladder fistula

Keywords: urinary bladder neoplasms diagnosis urine analysis spectroscopy fourier transform infrared raman spectrum analysis multivariate analysis
sugars-containing beverage and food intake in children

Conditions: Childhood Obesity

Summary: the purpose is to determine the effect of sugars in solution on food intake and subjective appetite in 9- to 14-year-old normal weight boys. the investigators hypothesize that food intake after all sugars-containing solutions will be decreased in comparison to the control solution, with similar reductions in fi between high-fructose corn syrup -55 (hfcs-55) and sucrose. food intake will be measured 60 minutes after consumption of 50g of hfcs-55, sucrose or glucose, or a control treatment. subjective appetite will be measured at 15, 30, 45, 60 and 90 minutes.


Eligibility criteria:
inclusion criteria: * healthy, boy, born at full term and normal birth weight exclusion criteria: * girl, on restricted diet, taking medication that affect appetite or food intake, have significant learning, behavioral, or emotional difficulties

Keywords: boys obesity glucose sucrose high-fructose corn syrup-55
study to evaluate safety, tolerability and efficacy of ucb7665 in subjects with primary immune thrombocytopenia

Conditions: Thrombocytopenia

Summary: the primary objective of the study is to check if an subcutaneous (sc) infusion of ucb7665 is safe and tolerated in subjects with primary immune thrombocytopenia.


Eligibility criteria:
inclusion criteria: * subject has a diagnosis of primary immune thrombocytopenia (itp) for a minimum of 3 months prior to screening visit * subject has a platelet count \<30x10\^9/l at screening and \<35x10\^9/l at baseline (visit 2) * subject has a current or history of a peripheral blood smear consistent with itp * subject has responded to previous itp therapy (according to the judgment of the investigator) exclusion criteria: * subject has an immunoglobulin g (igg) level \<=6g/l at screening visit * subject has a partial thromboplastin time (ptt) \>=1.5x upper limit of normal (uln) or international normalized ratio (inr) \>=1.5 at screening visit * subject has renal and/or liver impairment defined as: * serum creatinine level of \>=1.4 mg/dl for females and \>=1.5 mg/dl for males at screening visit * subject has planned an elective surgical procedure in the coming 6 months * subject has evidence of a secondary cause of primary immune thrombocytopenia purpura * subject has a history of clinically relevant ongoing chronic infections * subject has a family history of primary immunodeficiency * subject has a clinically relevant active infection or has had a serious infection within 6 weeks prior to the first dose of imp * subject has a history of known inflammatory bowel disease, diverticular disease, and gastric or esophageal ulceration * subject has experienced gastrointestinal bleed in the last 6 months prior to screening visit and/or has current gastritis or esophagitis * subject has a medical history of thrombosis * subject has a history of coagulopathy disorders other than itp * subject has received a live vaccination within 8 weeks prior to the baseline visit; or intends to have a live vaccination during the course of the study or within 7 weeks following the final dose of imp * subject has had prior treatment with rituximab in the 6 months prior to the baseline visit * subject has not completed the washout period for the immunosuppressants, biologics and other therapies

Keywords: itp